{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:31:57Z","timestamp":1792132317787,"version":"4.4.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Open access funding provided by the Qatar National Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Agonists of the glucagon-like peptide-1 receptor (GLP-1R), currently approved to treat type 2 diabetes, hold promise to improve steatosis and even steatohepatitis. However, due to their pleiotropic effects, the mechanisms underlying their protective effect on NAFLD remain elusive. We aimed to investigate these mechanisms using an in vitro model of steatosis treated with the GLP-1R agonist Exendin-4 (Ex-4). We established steatotic HepG2 cells by incubating the cells with 400\u00a0\u00b5M oleic acid (OA) overnight. Further treatment with 200\u00a0nM Ex-4 for 3\u00a0h significantly reduced the OA-induced lipid accumulation (p\u2009&lt;\u20090.05). Concomitantly, Ex-4 substantially reduced the expression levels of Fatty Acid-Binding Protein 1 (FABP1) and its primary activator, Forkhead box protein A1 (FOXA1). Interestingly, the silencing of \u03b2-catenin with siRNA abolished the effect of Ex-4 on these genes, suggesting dependency on the Wnt\/\u03b2-catenin pathway. Additionally, after \u03b2-catenin silencing, OA treatment significantly increased the expression of nuclear transcription factors SREBP-1 and TCF4, whereas Ex-4 significantly decreased this upregulation. Our findings suggest that direct activation of GLP-1R by Ex-4 reduces OA-induced steatosis in HepG2 cells by reducing fatty acid uptake and transport via FABP1 downregulation.<\/jats:p>","DOI":"10.1038\/s41598-022-06143-5","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:04:57Z","timestamp":1644404697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt\/-catenin signaling pathway"],"prefix":"10.1038","volume":"12","author":[{"given":"Olfa","family":"Khalifa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neyla S.","family":"AL-Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaoula","family":"Errafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelilah","family":"Arredouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"issue":"3","key":"6143_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. Non-alcoholic fatty liver disease\u2014A global public health perspective. J. Hepatol. 70(3), 531\u2013544 (2019).","journal-title":"J. Hepatol."},{"issue":"2","key":"6143_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar, D. et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A european liver transplant registry study. J. Hepatol. 71(2), 313\u2013322 (2019).","journal-title":"J. Hepatol."},{"issue":"7","key":"6143_CR3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter, T. G. & Rinella, M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology 158(7), 1851\u20131864 (2020).","journal-title":"Gastroenterology"},{"issue":"47","key":"6143_CR4","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","volume":"23","author":"BJ Perumpail","year":"2017","unstructured":"Perumpail, B. J. et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol. 23(47), 8263\u20138276 (2017).","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"6143_CR5","first-page":"64","volume":"36","author":"LM Glass","year":"2019","unstructured":"Glass, L. M., Hunt, C. M., Fuchs, M. & Su, G. L. Comorbidities and nonalcoholic fatty liver disease: The chicken, the egg, or both?. Fed. Pract. 36(2), 64\u201371 (2019).","journal-title":"Fed. Pract."},{"issue":"1","key":"6143_CR6","first-page":"1","volume":"8","author":"M Alves-Bezerra","year":"2017","unstructured":"Alves-Bezerra, M. & Cohen, D. E. Triglyceride metabolism in the liver. Compr. Physiol. 8(1), 1\u20138 (2017).","journal-title":"Compr. Physiol."},{"key":"6143_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijms20112841","volume":"20","author":"A Lonardo","year":"2019","unstructured":"Lonardo, A., Mantovani, A., Lugari, S. & Targher, G. NAFLD in some common endocrine diseases: Prevalence, pathophysiology, and principles of diagnosis and management. Int. J. Mol. Sci. 20, 11 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"6143_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/diseases6040091","volume":"6","author":"ER Yoo","year":"2018","unstructured":"Yoo, E. R. et al. When to initiate weight loss medications in the NAFLD population. Diseases 6, 4 (2018).","journal-title":"Diseases"},{"issue":"2","key":"6143_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3945\/an.116.013730","volume":"8","author":"CC Hsu","year":"2017","unstructured":"Hsu, C. C., Ness, E. & Kowdley, K. V. Nutritional approaches to achieve weight loss in nonalcoholic fatty liver disease. Adv. Nutr. 8(2), 253\u2013265 (2017).","journal-title":"Adv. Nutr."},{"issue":"2","key":"6143_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3727\/105221617X15124844266408","volume":"18","author":"DJ van der Windt","year":"2018","unstructured":"van der Windt, D. J., Sud, V., Zhang, H., Tsung, A. & Huang, H. The effects of physical exercise on fatty liver disease. Gene Expr. 18(2), 89\u2013101 (2018).","journal-title":"Gene Expr."},{"issue":"3","key":"6143_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","volume":"34","author":"JA Sargeant","year":"2019","unstructured":"Sargeant, J. A. et al. A Review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol. Metab. (Seoul). 34(3), 247\u2013262 (2019).","journal-title":"Endocrinol. Metab. (Seoul)."},{"key":"6143_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130 (2019).","journal-title":"Mol. Metab."},{"key":"6143_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/B978-0-12-800101-1.00002-8","volume":"121","author":"P Nadkarni","year":"2014","unstructured":"Nadkarni, P., Chepurny, O. G. & Holz, G. G. Regulation of glucose homeostasis by GLP-1. Prog. Mol. Biol. Transl. Sci. 121, 23\u201365 (2014).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"6143_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fendo.2018.00672","volume":"9","author":"J Rowlands","year":"2018","unstructured":"Rowlands, J., Heng, J., Newsholme, P. & Carlessi, R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front. Endocrinol. (Lausanne). 9, 672 (2018).","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"6","key":"6143_CR15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell, J. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17(6), 819\u2013837 (2013).","journal-title":"Cell Metab."},{"issue":"3","key":"6143_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/jdi.12906","volume":"10","author":"T Takase","year":"2019","unstructured":"Takase, T. et al. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. J. Diabet. Investig. 10(3), 699\u2013705 (2019).","journal-title":"J. Diabet. Investig."},{"issue":"1","key":"6143_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s13300-018-0560-8","volume":"10","author":"H Nagaike","year":"2019","unstructured":"Nagaike, H. et al. Effect of dulaglutide versus liraglutide on glucose variability, oxidative stress, and endothelial function in type 2 diabetes: A prospective study. Diabet. Ther. 10(1), 215\u2013228 (2019).","journal-title":"Diabet. Ther."},{"key":"6143_CR18","doi-asserted-by":"publisher","first-page":"212283","DOI":"10.7573\/dic.212283","volume":"4","author":"L Prasad-Reddy","year":"2015","unstructured":"Prasad-Reddy, L. & Isaacs, D. A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond. Drugs Context. 4, 212283 (2015).","journal-title":"Drugs Context."},{"issue":"2","key":"6143_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","volume":"64","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64(2), 399\u2013408 (2016).","journal-title":"J. Hepatol."},{"issue":"1","key":"6143_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1060028020935105","volume":"55","author":"JA Dougherty","year":"2021","unstructured":"Dougherty, J. A., Guirguis, E. & Thornby, K. A. A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann. Pharmacother. 55(1), 65\u201379 (2021).","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"6143_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","volume":"64","author":"R Bouchi","year":"2017","unstructured":"Bouchi, R. et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: A randomized control trial. Endocr. J. 64(3), 269\u2013281 (2017).","journal-title":"Endocr. J."},{"key":"6143_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/biomedicines9040353","volume":"9","author":"KL Hupa-Breier","year":"2021","unstructured":"Hupa-Breier, K. L. et al. Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH. Biomedicines. 9, 4 (2021).","journal-title":"Biomedicines."},{"issue":"8","key":"6143_CR23","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","volume":"22","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto, T. et al. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J. Gastroenterol. 22(8), 2512\u20132523 (2016).","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"6143_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbrc.2020.03.032","volume":"525","author":"X Han","year":"2020","unstructured":"Han, X. et al. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2\/HO-1 pathway. Biochem. Biophys. Res. Commun. 525(4), 895\u2013901 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"6143_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials. Metabolites. 11, 2 (2021).","journal-title":"Metabolites."},{"key":"6143_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fphar.2020.00432","volume":"11","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system. Front. Pharmacol. 11, 432 (2020).","journal-title":"Front. Pharmacol."},{"issue":"11","key":"6143_CR27","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay, M. S. et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial). Diabetologia 63(11), 2434\u20132445 (2020).","journal-title":"Diabetologia"},{"key":"6143_CR28","doi-asserted-by":"publisher","first-page":"600175","DOI":"10.3389\/fphar.2020.600175","volume":"11","author":"R Zhou","year":"2020","unstructured":"Zhou, R. et al. Liraglutide alleviates hepatic steatosis and liver injury in T2MD rats via a GLP-1R dependent AMPK pathway. Front Pharmacol. 11, 600175 (2020).","journal-title":"Front Pharmacol."},{"issue":"6","key":"6143_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s13300-021-01072-4","volume":"12","author":"T Song","year":"2021","unstructured":"Song, T. et al. Effects of liraglutide on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Ther. 12(6), 1735\u20131749 (2021).","journal-title":"Diabetes Ther."},{"issue":"5","key":"6143_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1248\/bpb.b14-00505","volume":"38","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. The Glucagon-like peptide-1 analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease. Biol. Pharm. Bull. 38(5), 694\u2013702 (2015).","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"6143_CR31","doi-asserted-by":"publisher","first-page":"16461","DOI":"10.1038\/s41598-018-33949-z","volume":"8","author":"MP Valdecantos","year":"2018","unstructured":"Valdecantos, M. P. et al. Differential effects of a glucagon-like peptide 1 receptor agonist in non-alcoholic fatty liver disease and in response to hepatectomy. Sci. Rep. 8(1), 16461 (2018).","journal-title":"Sci. Rep."},{"key":"6143_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.peptides.2017.11.016","volume":"100","author":"NJ Wewer Albrechtsen","year":"2018","unstructured":"Wewer Albrechtsen, N. J. Glucagon receptor signaling in metabolic diseases. Peptides 100, 42\u201347 (2018).","journal-title":"Peptides"},{"issue":"2","key":"6143_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jdi.12888","volume":"10","author":"WH Feng","year":"2019","unstructured":"Feng, W. H. et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J. Diabet. Investig. 10(2), 399\u2013407 (2019).","journal-title":"J. Diabet. Investig."},{"key":"6143_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trsl.2020.07.008","volume":"227","author":"E Somm","year":"2021","unstructured":"Somm, E. et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Transl. Res. 227, 75\u201388 (2021).","journal-title":"Transl. Res."},{"issue":"Suppl 1","key":"6143_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S1262-3636(17)30185-4","volume":"43","author":"JM Petit","year":"2017","unstructured":"Petit, J. M. & Verg\u00e8s, B. GLP-1 receptor agonists in NAFLD. Diabetes Metab. 43(Suppl 1), 28\u201333 (2017).","journal-title":"Diabetes Metab."},{"issue":"5","key":"6143_CR36","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta, N. A. et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51(5), 1584\u20131592 (2010).","journal-title":"Hepatology"},{"issue":"12","key":"6143_CR37","doi-asserted-by":"publisher","first-page":"e0166913","DOI":"10.1371\/journal.pone.0166913","volume":"11","author":"MH Seo","year":"2016","unstructured":"Seo, M. H. et al. Exendin-4 inhibits hepatic lipogenesis by increasing \u03b2-catenin signaling. PLoS ONE 11(12), e0166913 (2016).","journal-title":"PLoS ONE"},{"key":"6143_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4081\/ejh.2020.3160","volume":"64","author":"Z Gao","year":"2020","unstructured":"Gao, Z. et al. \u03b2-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet. Eur. J. Histochem. 64, 3 (2020).","journal-title":"Eur. J. Histochem."},{"issue":"7","key":"6143_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.biocel.2009.09.001","volume":"43","author":"SP Monga","year":"2011","unstructured":"Monga, S. P. Role of Wnt\/\u03b2-catenin signaling in liver metabolism and cancer. Int. J. Biochem. Cell Biol. 43(7), 1021\u20131029 (2011).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"6143_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-pathol-020117-044010","volume":"13","author":"JO Russell","year":"2018","unstructured":"Russell, J. O. & Monga, S. P. Wnt\/\u03b2-catenin signaling in liver development, homeostasis, and pathobiology. Annu. Rev. Pathol. 13, 351\u2013378 (2018).","journal-title":"Annu. Rev. Pathol."},{"key":"6143_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijms17122082","volume":"17","author":"S Petta","year":"2016","unstructured":"Petta, S. et al. Pathophysiology of non alcoholic fatty liver disease. Int. J. Mol. Sci. 17, 12 (2016).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"6143_CR42","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-16-0513","volume":"234","author":"CE Geisler","year":"2017","unstructured":"Geisler, C. E. & Renquist, B. J. Hepatic lipid accumulation: Cause and consequence of dysregulated glucoregulatory hormones. J. Endocrinol. 234(1), R1-r21 (2017).","journal-title":"J. Endocrinol."},{"issue":"4","key":"6143_CR43","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3892\/etm.2016.3069","volume":"11","author":"MJ Alkhatatbeh","year":"2016","unstructured":"Alkhatatbeh, M. J., Lincz, L. F. & Thorne, R. F. Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG(2) cells: An in vitro model of non-alcoholic fatty liver disease. Exp. Ther. Med. 11(4), 1487\u20131492 (2016).","journal-title":"Exp. Ther. Med."},{"key":"6143_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21769\/BioProtoc.1912","volume":"6","author":"B Qiu","year":"2016","unstructured":"Qiu, B. & Simon, M. C. BODIPY 493\/503 staining of neutral lipid droplets for microscopy and quantification by flow cytometry. Bio Protoc. 6, 17 (2016).","journal-title":"Bio Protoc."},{"issue":"1","key":"6143_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12967-021-02885-4","volume":"19","author":"K Errafii","year":"2021","unstructured":"Errafii, K., Al-Akl, N. S., Khalifa, O. & Arredouani, A. Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. J. Transl. Med. 19(1), 235 (2021).","journal-title":"J. Transl. Med."},{"issue":"1","key":"6143_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12944-017-0473-y","volume":"16","author":"H Itabe","year":"2017","unstructured":"Itabe, H., Yamaguchi, T., Nimura, S. & Sasabe, N. Perilipins: a diversity of intracellular lipid droplet proteins. Lipids Health Dis. 16(1), 83 (2017).","journal-title":"Lipids Health Dis."},{"key":"6143_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-nutr-071813-105410","volume":"36","author":"AR Kimmel","year":"2016","unstructured":"Kimmel, A. R. & Sztalryd, C. The perilipins: Major cytosolic lipid droplet-associated proteins and their roles in cellular lipid storage, mobilization, and systemic homeostasis. Annu. Rev. Nutr. 36, 471\u2013509 (2016).","journal-title":"Annu. Rev. Nutr."},{"issue":"7","key":"6143_CR48","doi-asserted-by":"publisher","first-page":"E770","DOI":"10.1152\/ajpendo.00523.2012","volume":"304","author":"W Chen","year":"2013","unstructured":"Chen, W. et al. Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice. Am. J. Physiol. Endocrinol. Metab. 304(7), E770\u2013E779 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"8","key":"6143_CR49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1139\/apnm-2018-0729","volume":"44","author":"W Zhong","year":"2019","unstructured":"Zhong, W., Fan, B., Cong, H., Wang, T. & Gu, J. Oleic acid-induced perilipin 5 expression and lipid droplets formation are regulated by the PI3K\/PPAR\u03b1 pathway in HepG2 cells. Appl. Physiol. Nutr. Metab. 44(8), 840\u2013848 (2019).","journal-title":"Appl. Physiol. Nutr. Metab."},{"issue":"1","key":"6143_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cgh.2016.08.023","volume":"15","author":"RM Carr","year":"2017","unstructured":"Carr, R. M. et al. Perilipin staining distinguishes between steatosis and nonalcoholic steatohepatitis in adults and children. Clin. Gastroenterol. Hepatol. 15(1), 145\u2013147 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"6143_CR51","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1038\/s41467-019-10684-1","volume":"10","author":"MT Hackl","year":"2019","unstructured":"Hackl, M. T. et al. Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. Nat. Commun. 10(1), 2717 (2019).","journal-title":"Nat. Commun."},{"issue":"6","key":"6143_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi, M. & Hotamisligil, G. S. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7(6), 489\u2013503 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"6143_CR53","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1194\/jlr.R056705","volume":"56","author":"G Wang","year":"2015","unstructured":"Wang, G., Bonkovsky, H. L., de Lemos, A. & Burczynski, F. J. Recent insights into the biological functions of liver fatty acid binding protein 1. J. Lipid Res. 56(12), 2238\u20132247 (2015).","journal-title":"J. Lipid Res."},{"issue":"2","key":"6143_CR54","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1388-1981(99)00008-6","volume":"1437","author":"C Wolfrum","year":"1999","unstructured":"Wolfrum, C., Buhlmann, C., Rolf, B., B\u00f6rchers, T. & Spener, F. Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim. Biophys. Acta. 1437(2), 194\u2013201 (1999).","journal-title":"Biochim. Biophys. Acta."},{"issue":"24","key":"6143_CR55","doi-asserted-by":"publisher","first-page":"21429","DOI":"10.1074\/jbc.M300287200","volume":"278","author":"GG Martin","year":"2003","unstructured":"Martin, G. G. et al. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J. Biol. Chem. 278(24), 21429\u201321438 (2003).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"6143_CR56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/en.2012-1937","volume":"154","author":"N Panjwani","year":"2013","unstructured":"Panjwani, N. et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice. Endocrinology 154(1), 127\u2013139 (2013).","journal-title":"Endocrinology"},{"key":"6143_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjgast-2019-000370","volume":"7","author":"H Yokomori","year":"2020","unstructured":"Yokomori, H. & Ando, W. Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis. BMJ Open Gastroenterol. 7, 1 (2020).","journal-title":"BMJ Open Gastroenterol."},{"issue":"3","key":"6143_CR58","doi-asserted-by":"publisher","first-page":"e0193473","DOI":"10.1371\/journal.pone.0193473","volume":"13","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis. PLoS ONE 13(3), e0193473 (2018).","journal-title":"PLoS ONE"},{"issue":"7","key":"6143_CR59","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/2211-5463.12240","volume":"7","author":"T Mukai","year":"2017","unstructured":"Mukai, T., Egawa, M., Takeuchi, T., Yamashita, H. & Kusudo, T. Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. FEBS Open Bio. 7(7), 1009\u20131016 (2017).","journal-title":"FEBS Open Bio."},{"issue":"1","key":"6143_CR60","doi-asserted-by":"publisher","first-page":"G307","DOI":"10.1152\/ajpgi.00377.2007","volume":"294","author":"EP Newberry","year":"2008","unstructured":"Newberry, E. P. et al. Diet-induced obesity and hepatic steatosis in L-Fabp \/ mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Am. J. Physiol. Gastrointest. Liver Physiol. 294(1), G307\u2013G314 (2008).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"4","key":"6143_CR61","doi-asserted-by":"publisher","first-page":"e0214144","DOI":"10.1371\/journal.pone.0214144","volume":"14","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Fatty acid-binding protein 1 increases steer fat deposition by facilitating the synthesis and secretion of triacylglycerol in liver. PLoS ONE 14(4), e0214144 (2019).","journal-title":"PLoS ONE"},{"issue":"5","key":"6143_CR62","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/hep.23343","volume":"50","author":"M Charlton","year":"2009","unstructured":"Charlton, M. Medical hurricane: Health care reform and hepatology. Hepatology 50(5), 1339\u20131340 (2009).","journal-title":"Hepatology"},{"key":"6143_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev.nutr.17.1.77","volume":"17","author":"KH Kim","year":"1997","unstructured":"Kim, K. H. Regulation of mammalian acetyl-coenzyme A carboxylase. Annu. Rev. Nutr. 17, 77\u201399 (1997).","journal-title":"Annu. Rev. Nutr."},{"issue":"22","key":"6143_CR64","doi-asserted-by":"publisher","first-page":"13018","DOI":"10.1073\/pnas.95.22.13018","volume":"95","author":"S Cases","year":"1998","unstructured":"Cases, S. et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc. Natl. Acad. Sci. U.S.A. 95(22), 13018\u201313023 (1998).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"6143_CR65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.22980","volume":"50","author":"CJ Villanueva","year":"2009","unstructured":"Villanueva, C. J. et al. Specific role for acyl CoA: Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 50(2), 434\u2013442 (2009).","journal-title":"Hepatology"},{"issue":"3","key":"6143_CR66","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1172\/JCI27300","volume":"116","author":"DB Savage","year":"2006","unstructured":"Savage, D. B. et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116(3), 817\u2013824 (2006).","journal-title":"J. Clin. Invest."},{"issue":"29","key":"6143_CR67","doi-asserted-by":"publisher","first-page":"25655","DOI":"10.1074\/jbc.M111.228692","volume":"286","author":"K Lee","year":"2011","unstructured":"Lee, K., Kerner, J. & Hoppel, C. L. Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part of an outer membrane fatty acid transfer complex. J. Biol. Chem. 286(29), 25655\u201325662 (2011).","journal-title":"J. Biol. Chem."},{"key":"6143_CR68","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev.nutr.20.1.169","volume":"20","author":"NO Davidson","year":"2000","unstructured":"Davidson, N. O. & Shelness, G. S. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. 20, 169\u2013193 (2000).","journal-title":"Annu. Rev. Nutr."},{"issue":"11","key":"6143_CR69","doi-asserted-by":"publisher","first-page":"e49152","DOI":"10.1371\/journal.pone.0049152","volume":"7","author":"ET Parlevliet","year":"2012","unstructured":"Parlevliet, E. T. et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS ONE 7(11), e49152 (2012).","journal-title":"PLoS ONE"},{"issue":"4","key":"6143_CR70","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.bbalip.2012.12.014","volume":"1831","author":"C Guzm\u00e1n","year":"2013","unstructured":"Guzm\u00e1n, C. et al. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPAR\u03b1; and repressed by C\/EBP\u03b1: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim. Biophys. Acta. 1831(4), 803\u2013818 (2013).","journal-title":"Biochim. Biophys. Acta."},{"issue":"1","key":"6143_CR71","doi-asserted-by":"publisher","first-page":"e30014","DOI":"10.1371\/journal.pone.0030014","volume":"7","author":"M Moya","year":"2012","unstructured":"Moya, M. et al. Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver. PLoS ONE 7(1), e30014 (2012).","journal-title":"PLoS ONE"},{"issue":"12","key":"6143_CR72","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","volume":"13","author":"H Shimano","year":"2017","unstructured":"Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology\u2014divergent pathophysiology. Nat. Rev. Endocrinol. 13(12), 710\u2013730 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"6143_CR73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.molcel.2013.05.013","volume":"51","author":"J Wang","year":"2013","unstructured":"Wang, J. et al. TRIB2 acts downstream of Wnt\/TCF in liver cancer cells to regulate YAP and C\/EBP\u03b1 function. Mol. Cell. 51(2), 211\u2013225 (2013).","journal-title":"Mol. Cell."},{"issue":"4","key":"6143_CR74","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1128\/JVI.02604-15","volume":"90","author":"YL Wu","year":"2016","unstructured":"Wu, Y. L. et al. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. J. Virol. 90(4), 1729\u20131740 (2016).","journal-title":"J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06143-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06143-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:21:24Z","timestamp":1669328484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06143-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6143"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06143-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"12 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2226"}}